Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.

Ilinca D MetesLingshu XueChung-Chou H ChangHaiden A HuskampWalid F GelladWei-Hsuan Lo-CiganicNiteesh K ChoudhrySeth Richards-ShubikHasan GucluJulie M Donohue

Published in: BMC health services research (2019)

In a medication market with many choices, county-level adoption of sitagliptin was positively associated with AD spending in Medicare and Medicaid, two programs with different approaches to formulary management.

Keyphrases

affordable care act
health insurance
adverse drug
electronic health record
healthcare
emergency department
primary care
type diabetes
public health